NCT00735228

Brief Summary

Hyperglycaemia has been repeatedly associated with risk of mortality and morbidity in the intensive care unit (ICU). The evidence currently available is in favour of a 'normal ≤ 6.1 mmol/l' level for blood glucose control in ICUs according to two large randomized control trials of Van den Berghe G and is not supportive of J. Miles's viewpoint in this debate. In this study, the investigators would like to evaluate that the target of blood glucose level, whether is a normal level (80-110 mg/dL) or another level (140-160 mg/dL), should be set for the reduction of perioperative mortality and complications.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2008

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2008

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

August 12, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 14, 2008

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2012

Completed
Last Updated

August 18, 2008

Status Verified

August 1, 2008

Enrollment Period

4 years

First QC Date

August 12, 2008

Last Update Submit

August 15, 2008

Conditions

Keywords

surgeryartificial pancreastight glycemic controlLiver

Outcome Measures

Primary Outcomes (1)

  • The incidence of hypoglycemia

    during hospitalization

Secondary Outcomes (1)

  • The incidence of postoperative infectious complications and calculate the total costs during hospitalization

    during hospitalization

Study Arms (2)

1

ACTIVE COMPARATOR

Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.

Device: Artificial pancreas

2

ACTIVE COMPARATOR

Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.

Device: Artificial pancreas

Interventions

Artificial endocrine pancreas (NIKKISO Company)

Also known as: artificial endocrine pancreas (NIKKISO Company)
12

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who were suffering from liver, pancreas or cardio-vascular diseases, were informed of the purpose and details of the study, and written consent was obtained from them prior to enrolment.

You may not qualify if:

  • The presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal or heart disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kochi Medical School

Nankoku, 783-8505, Japan

RECRUITING

Related Publications (1)

  • Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Sugimoto T, Kobayashi M, Yokoyama M, Hanazaki K. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care. 2014 Jun;37(6):1516-24. doi: 10.2337/dc13-1771. Epub 2014 Mar 12.

MeSH Terms

Conditions

Pancreatic DiseasesCardiovascular Diseases

Interventions

Pancreas, ArtificialInsulin Infusion Systems

Condition Hierarchy (Ancestors)

Digestive System Diseases

Intervention Hierarchy (Ancestors)

Artificial OrgansSurgical EquipmentEquipment and SuppliesDrug Delivery SystemsDrug TherapyTherapeuticsInfusion Pumps

Study Officials

  • Takehiro Okabayashi, MD, PhD

    Kochi Medical School

    STUDY DIRECTOR

Central Study Contacts

Takehiro Okabayashi, MD, PhD

CONTACT

Kazuhiro Hanazaki, Prof

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 12, 2008

First Posted

August 14, 2008

Study Start

August 1, 2008

Primary Completion

August 1, 2012

Study Completion

August 1, 2012

Last Updated

August 18, 2008

Record last verified: 2008-08

Locations